EA201592222A1 - Способы получения частиц, содержащих терапевтические белки - Google Patents

Способы получения частиц, содержащих терапевтические белки

Info

Publication number
EA201592222A1
EA201592222A1 EA201592222A EA201592222A EA201592222A1 EA 201592222 A1 EA201592222 A1 EA 201592222A1 EA 201592222 A EA201592222 A EA 201592222A EA 201592222 A EA201592222 A EA 201592222A EA 201592222 A1 EA201592222 A1 EA 201592222A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
polymer matrix
combining
methods
particles containing
Prior art date
Application number
EA201592222A
Other languages
English (en)
Inventor
Сара Маркетт
Эндрю Ятс
Клод Пербом
Original Assignee
Юсб Биофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201592222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP13168674.3A external-priority patent/EP2805708A1/en
Application filed by Юсб Биофарма Спрл filed Critical Юсб Биофарма Спрл
Publication of EA201592222A1 publication Critical patent/EA201592222A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к области фармацевтических препаратов. Конкретнее, изобретение относится к способу получения частицы, содержащей полимерную матрицу и белок. Способ включает следующие стадии: а) отвердение белка из раствора, содержащего белок; b) объединение отвердевшего белка с растворителем, содержащим полимерную матрицу; с) объединение растворителя, содержащего полимерную матрицу и белок, с эмульгатором в воде; d) перемешивание растворителя, содержащего полимерную матрицу, белок и эмульгатор, для образования эмульсии; е) объединение эмульсии, содержащей полимерную матрицу и белок, с водой для допуска образования частиц; и f) извлечение частиц. Кроме того, предложены частица, содержащая полимерную матрицу и белок, полученная с помощью этого способа, а также фармацевтическая композиция, содержащим указанную частицу. Настоящее изобретение обеспечивает усовершенствованный способ получения частиц на основе полимерной матрицы с повышенной эффективностью инкапсуляции.
EA201592222A 2013-05-22 2014-05-21 Способы получения частиц, содержащих терапевтические белки EA201592222A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13168674.3A EP2805708A1 (en) 2013-05-22 2013-05-22 Methods to produce particles comprising therapeutic proteins
EP14161988 2014-03-27
PCT/EP2014/060450 WO2014187863A1 (en) 2013-05-22 2014-05-21 Methods to produce particles comprising therapeutic proteins

Publications (1)

Publication Number Publication Date
EA201592222A1 true EA201592222A1 (ru) 2016-08-31

Family

ID=50877246

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592222A EA201592222A1 (ru) 2013-05-22 2014-05-21 Способы получения частиц, содержащих терапевтические белки

Country Status (14)

Country Link
US (1) US20160090415A1 (ru)
EP (1) EP2999459A1 (ru)
JP (1) JP2016519152A (ru)
KR (1) KR20160009690A (ru)
CN (1) CN105338961A (ru)
AU (1) AU2014270439A1 (ru)
BR (1) BR112015028986A2 (ru)
CA (1) CA2912730A1 (ru)
CL (1) CL2015003420A1 (ru)
EA (1) EA201592222A1 (ru)
HK (1) HK1214964A1 (ru)
MX (1) MX2015015899A (ru)
SG (1) SG11201509450QA (ru)
WO (1) WO2014187863A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528248A (ja) * 2016-07-18 2019-10-10 ティシュージェン， インク． 生体分子の立体配座及び構造健全性を維持するための方法及び組成物
CN112336873B (zh) 2020-08-04 2022-04-19 华南理工大学 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
EP2044934A1 (en) * 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof

Also Published As

Publication number Publication date
BR112015028986A2 (pt) 2017-07-25
JP2016519152A (ja) 2016-06-30
WO2014187863A1 (en) 2014-11-27
US20160090415A1 (en) 2016-03-31
CL2015003420A1 (es) 2016-09-30
CN105338961A (zh) 2016-02-17
EP2999459A1 (en) 2016-03-30
HK1214964A1 (zh) 2016-08-12
SG11201509450QA (en) 2015-12-30
AU2014270439A1 (en) 2015-12-17
CA2912730A1 (en) 2014-11-27
KR20160009690A (ko) 2016-01-26
MX2015015899A (es) 2016-07-15

Similar Documents

Publication Publication Date Title
EA201892693A1 (ru) Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
EA201890883A1 (ru) Вакуумная дистилляция для обогащения каннабидиола
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
CY1123672T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CL2018000238A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
EA201690504A1 (ru) Антигенсвязывающие белки к gitr
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201500208A1 (ru) Слитые белки, содержащие интерлейкин-10, и их применения
TR201902469T4 (tr) Sertleşebilir iki parçalı akrilik bileşim üretilmesine yönelik yöntem.
WO2015089492A3 (en) Dna antibody constructs and method of using same
EA201690898A1 (ru) Способы лечения таупатии
EA201291404A1 (ru) Концентрация и лиофилизация вакцинных антигенов гриппа
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX2015015409A (es) Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos.
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
FR3044001B1 (fr) Procede de preparation d'un materiau adsorbant comprenant une etape de malaxage basique et procede d'extraction de lithium a partir de solutions salines utilisant ledit materiau